Etanercept
Brand: Enbrel / Intacept
Immunomodulator
TNF-alpha inhibitor (receptor-Fc fusion protein)
Pharmacokinetics
| Half-life | 4 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Given SC. Fusion protein of TNF receptor–Fc. Lower immunogenicity than infliximab. Infection risk similar to other TNF blockers. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Injection-site reactions, serious infections (TB, fungal), reactivation of HBV, demyelinating disease, neutropenia
Contraindications:
Active infection, untreated TB
Precautions:
Screen TB & HBV before therapy; avoid live vaccines; monitor CBC; caution in demyelinating disorders